10 Lymphoma Clinical Trials in Indianapolis, IN (2026)

Q: How do I join a clinical trial in Indianapolis?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you.

Recruiting Lymphoma Studies in Indianapolis

NCT06091865Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Ly...

Indianapolis, INPHASE3904 participantsRegeneron Pharmaceuticals

View Study Details

NCT07516093Recruiting

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymph...

Indianapolis, INPHASE3620 participantsNurix Therapeutics, Inc.

View Study Details

NCT06149286Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of canc...

Indianapolis, INPHASE3580 participantsRegeneron Pharmaceuticals

View Study Details

NCT05826535Recruiting

Study of LYL314 in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 ...

Indianapolis, INPHASE1270 participantsLyell Immunopharma, Inc.

View Study Details

NCT06084936Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len...

Indianapolis, INPHASE3182 participantsHoffmann-La Roche

View Study Details

NCT04920617Recruiting

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refr...

Indianapolis, INPHASE2102 participantsImmunoVaccine Technologies, Inc. (IMV Inc.)

View Study Details

NCT03681561Recruiting

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose...

Indianapolis, INPHASE154 participantsVeronika Bachanova

View Study Details

NCT05852717Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Da...

Indianapolis, INPHASE235 participantsDipenkumar Modi

View Study Details

NCT06484920Recruiting

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgki...

Indianapolis, INPHASE224 participantsRita Assi

View Study Details

NCT03829540Recruiting

CD4CAR for CD4+ Leukemia and Lymphoma

This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell l...

Indianapolis, INPHASE120 participantsHuda Salman

View Study Details

About Lymphoma Clinical Trials in Indianapolis

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 10 lymphoma clinical trials recruiting participants in Indianapolis, IN. These studies are seeking a combined 2,791 participants. Research is being sponsored by Regeneron Pharmaceuticals, Nurix Therapeutics, Inc., Lyell Immunopharma, Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Indianapolis — FAQ

Are there lymphoma clinical trials in Indianapolis?

Yes, there are 10 lymphoma clinical trials currently recruiting in Indianapolis, IN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Indianapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.

Are clinical trials in Indianapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 10 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated August 31, 2026 from ClinicalTrials.gov